Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/ASO.2005.10.005
Annals of Surgical Oncology 12:733-742 (2005)
© 2005 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Canter, R. J.
Right arrow Articles by Fraker, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Canter, R. J.
Right arrow Articles by Fraker, D. L.

Original Article

Suppression of ß-Catenin by Antisense Oligomers Augments Tumor Response to Isolated Limb Perfusion in a Rodent Model of Adenomatous Polyposis Coli–Mutant Colon Cancer

Robert J. Canter, MD1, Susan B. Kesmodel, MD1, Daniel F. Heitjan, PhD2, Nirmal K. Veeramachaneni, MD3, Nahush A. Mokadam, MD3, Jeffrey A. Drebin, MD, PhD1 and Douglas L. Fraker, MD1

1 Department of Surgery, University of Pennsylvania School of Medicine, 3400 Spruce Street, 4 Silverstein, Philadelphia, Pennsylvania 19104
2 Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, 622 Blockley Hall, 423 Grandian Drive, Philadelphia, Pennsylvania 19104
3 Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, Missouri 63110

Correspondence: Address correspondence and reprint requests to: Douglas L. Fraker, MD; E-mail: frakerd{at}uphs.upenn.edu.

Background: Isolated hepatic perfusion has been used in patients with colorectal cancer (CRC) metastatic to the liver. We sought to determine whether perfusion with antisense oligodeoxynucleotides results in the downregulation of ß-catenin and whether this improves tumor response to isolated limb perfusion (ILP) in a heterotopic model of human CRC.

Methods: Adenomatous polyposis coli–mutant human CRC xenografts were implanted into athymic rats. Animals were randomized to the following groups: (1) no treatment, (2) control ILP, (3) melphalan ILP, (4) ILP with antisense specific for ß-catenin, (5) ILP with nonspecific antisense, and (6) melphalan plus ß-catenin–specific antisense ILP. Tumor response and Western blot analysis of protein expression were evaluated.

Results: The maximal decrease (mean ± SE) in tumor volume was 0% ± 10% for no treatment, 19% ± 14% for control ILP, 58% ± 3% for melphalan ILP, 58% ± 9% for ß-catenin–specific ILP, 13% ± 19% for nonspecific antisense ILP, and 73% ± 6% for melphalan plus ß-catenin–specific ILP (P < .05 for melphalan ILP, ß-catenin–specific ILP, and melphalan plus antisense ILP). Tumor regrowth was delayed for 6 days after control ILP, 24 days after melphalan ILP, 20 days after ß-catenin–specific ILP, 10 days after nonspecific antisense ILP, and 60 days after melphalan plus ß-catenin–specific ILP (P < .05 for melphalan plus ß-catenin–specific ILP compared with all others). Western blotting revealed prolonged suppression of ß-catenin expression after ß-catenin–specific ILP.

Conclusions: Short-term ß-catenin antisense treatment improves tumor response rates after ILP in a rodent model of human CRC.

Key Words: Isolated limb perfusion • ß-Catenin antisense • Adenomatous polyposis coli • Hepatic metastases






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the Society of Surgical Oncology.